Safety Templates

The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) Working Group has developed standardized templates for benefit-risk assessments of new vaccine candidates.

(Total Items: [sbs_posts cat="vaccine-safety-templates"])

(1 - 12 of 17)

August 27, 2024

This manuscript uses the BRAVATO template to report the key considerations for a benefit-risk assessment of the coronavirus disease 2019 (COVID-19) mRNA-based vaccine[...]

October 26, 2023

This paper uses a BRAVATO protein template to review the features of Novavax’s recombinant adjuvanted spike protein vaccine to prevent disease caused by[...]

October 13, 2023

Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has[...]

October 13, 2023

Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology[...]

October 13, 2023

Replication-incompetent adenoviral vectors have been under investigation as a platform to carry a variety of transgenes, and express them as a basis for vaccine development.[...]

October 4, 2023

The Modified Vaccinia Ankara (MVA) vector system is being explored as a platform for development of multiple vaccines. This paper reviews the molecular and biological[...]

April 6, 2023

This paper uses a BRAVATO protein template to review the features of Medigen’s recombinant SARS-CoV-2 spike protein in prefusion stabilized form used to[...]

August 19, 2022

The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) was formed to evaluate the safety and other key features of new platform[...]

August 19, 2022

This paper uses the BRAVATO inactivated virus vaccine template to review the features of an inactivated whole chikungunya virus (CHIKV) vaccine that has been evaluated in several preclinical[...]

August 19, 2022

This paper uses a BRAVATO nucleic acid template to review the features of Moderna’s rapid-response proprietary vaccine platform based on an mRNA delivery[...]

September 7, 2021

Auro Vaccines LLC has developed a protein vaccine to prevent disease from Nipah and Hendra virus infection that employs a recombinant soluble Hendra glycoprotein (HeV-sG) adjuvanted with aluminum[...]

August 18, 2020

Several inactivated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration (BC) Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO), as[...]